The Food and Drug Administration (FDA) is responsible for ensuring that medical devices are safe and effective before they go on the market. Section 510(k) of the Federal Food, Drug, and Cosmetic Act requires a manufacturer of medical devices to notify FDA of its intent to market a medical device at least 90 days in advance. That window of time allows FDA to evaluate whether the device is substantially equivalent to a product already legally on the market (called a predicate), in which case the device does not need to go through the premarket approval (PMA) process. As part of its assessment of the FDA's premarket clearance process for medical devices, the Institute of Medicine (IOM) held a workshop on July 28, 2010 to discuss how medical devices are monitored for safety after they are available to consumers. Its primary focus was on monitoring the safety of marketed medical devices, including FDA's postmarket surveillance activities, analysis of safety concerns that resulted in medical device recalls, and non-FDA sources of adverse-event information. Public Health Effectiveness of the FDA 501(K) Clearance Process summarizes the views of the workshop participants.
1 Front Matter; 2 1 Introduction; 3 2 Food and Drug Administration Postmarket Surveillance Activities and Recall Studies of Medical Devices; 4 3 Non-Food and Drug Administration Sources of Adverse Event Data; 5 4 Postmarket Surveillance of Medical Devices: Panel Discussion; 6 5 Other Select Topics; 7 Appendix A: Workshop Agenda; 8 Appendix B: Biographic Information on Invited Speakers, Panelists, and Authors of Commissioned Papers; 9 Appendix C: 510(k) Premarket Notification Analysis of FDA Recall Data; 10 Appendix D: Trustworthy Medical Device Software
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Population Health and Public Health Practice, Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process, Theresa Wizemann
Institute of Medicine, Board on Population Health and Public Health Practice, Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process
Institute of Medicine, Board on Population Health and Public Health Practice, Roundtable on Population Health Improvement, Theresa Wizemann, Darla Thompson
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Population Health and Public Health Practice, Roundtable on Population Health Improvement, Darla Thompson, Theresa Wizemann
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Population Health and Public Health Practice, Roundtable on Population Health Improvement, Theresa Wizemann
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Population Health and Public Health Practice, Roundtable on Population Health Improvement, Theresa Wizemann